A detailed history of Citigroup Inc transactions in Gh Research PLC stock. As of the latest transaction made, Citigroup Inc holds 31 shares of GHRS stock, worth $434. This represents 0.0% of its overall portfolio holdings.

Number of Shares
31
Holding current value
$434
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

BUY
$11.8 - $19.5 $365 - $604
31 New
31 $0

Others Institutions Holding GHRS

About GH Research PLC


  • Ticker GHRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,020,800
  • Market Cap $728M
  • Description
  • GH Research PLC, a clinical-stage biopharmaceutical company, engages in developing various therapies for the treatment of psychiatric and neurological disorders. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD). Its lead program is GH0...
More about GHRS
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.